

SCIENTIFIC PROGRAM

FRIDAY, 27 FEBRUARY 2009

09.00 – 10.15

AUDITORIUM

PARALLEL SESSION III

HAEMOVIGILANCE IN SPECIFIC CLINICAL SITUATIONS

Chair: C. Taylor (*United Kingdom*), A. Zanella (*Italy*)

- 09.00 – 09.25 **Haemovigilance and the Junior Hospital Doctor**
C. Taylor (*United Kingdom*)
- 09.25 – 09.50 **Haemovigilance in Critical Care**
N. Soni (*United Kingdom*)
- 09.50 – 10.15 **Haemovigilance in the paediatric and neonatal setting**
H. New (*United Kingdom*)

09.00 – 10.45

AULA MOSCATI

PARALLEL SESSION IV

HAEMOVIGILANCE IN PRACTICE

Chair: P. Strengers (*The Netherlands*), G. Grazzini (*Italy*)

- 09.00 – 09.25 **TRALI: implementation of measures in Germany**
B. Keller-Stanislawski (*Germany*)
- 09.25 – 09.45 **Transfusion related lung injury following peripheral blood stem cell transfusion**
R. Alcantara (*Singapore*)
- 09.45 – 10.05 **TRIP project: Can incident reporting be improved?**
A. van Tilborgh (*The Netherlands*), J. Wiersum (*The Netherlands*)
- 10.05 – 10.25 **Prevention of antibody-mediated TRALI using a male only plasma strategy and leukocyte antibody screening of parous female blood donors**
A. Reil (*Germany*)
- 10.25 – 10.45 **Coffee/tea break**

SCIENTIFIC PROGRAM

10.45 – 12.00

AUDITORIUM

PARALLEL SESSION III *(continued)*

HAEMOVIGILANCE IN SPECIFIC CLINICAL SITUATIONS

Chair: C. Taylor *(United Kingdom)*, A. Zanella *(Italy)*

- 10.45 – 11.10 **Developing an adverse event reporting system for cell salvage incidents**
J. Jones *(United Kingdom)*
- 11.10 – 11.35 **Risk of transfusion contamination during an outbreak of Q fever in France 2007**
G. Daurat *(France)*
- 11.35 – 12.00 **The impact on the vigilance system of recent Chikungunya and WNV outbreak in Italy**
G. Liembruno *(Italy)*

10.45 – 12.00

AULA MOSCATI

PARALLEL SESSION IV *(continued)*

HAEMOVIGILANCE IN PRACTICE

Chair: P. Strengers *(The Netherlands)*, G. Grazzini *(Italy)*

- 10.45 – 11.10 **Annual notifications of serious adverse reactions and events Ireland -2006-2007**
J. Sweeney *(Ireland)*
- 11.10 – 11.35 **Role of the National Haemovigilance Committee. Perspectives of Haemovigilance in France**
C. Caldani *(France)*
- 11.35 – 12.00 **Blood safety in Greece: a report from the coordinating Haemovigilance Centre (SKAE) for the years 1996-2007**
C. Politis *(Greece)*
- 12.00 – 13.45 **Lunch**

12.45 – 13.45

AUDITORIUM

SPECIAL LUNCH SYMPOSIUM BY CERUS

The Role of Haemovigilance In The Implementation of Pathogen Inactivation Technologies

Laurence Corash, MD; Medical Affairs Cerus Corporation, Department of Laboratory Medicine, University of California, San Francisco.
“Experience With An Active Haemovigilance Program: Analysis of 35,000 Transfusions With Pathogen Inactivated Components” *(20 minutes)*

SCIENTIFIC PROGRAM

Jean Claude Osselaer, MD, JD; Transfusion Center, Cliniques Universitaires de Mont Godinne, Université Catholique de Louvain, Yvoir, Belgium. "Patient Outcomes Before and After Implementation of Pathogen Inactivation: A Six Year Experience" (40 minutes)

13.45 – 16.55

AUDITORIUM

PLENARY SESSION III

NEW PROJECTS AND FUTURE DIRECTIONS

Chair: J.C. Faber (*Luxembourg*), G. d'Onofrio (*Italy*)

- 13.45 – 14.00 **Applications of tele-medicine to the transfusion process**
P. Pagliaro (*Italy*)
- 14.00 – 14.25 **Experiences with the first year of reporting SAR and SAE to the EU**
T. Brégeon (*Belgium*)
- 14.25 – 14.50 **The EHN data base: establishment and first results**
C. Politis (*Greece*), P. Robillard (*Canada*)
- 14.50 – 15.15 **Donation Vigilance: The surveillance of adverse events related blood donors and blood donation process**
J. Jørgensen (*Denmark*)
- 15.15 – 15.45 **Coffee/tea break**
- 15.45 – 16.10 **Materio-vigilance**
B. Bugat (*France*)
- 16.10 – 16.45 **Biovigilance in the USA**
M. Strong (*USA*)
- 16.45 – 16.55 **The International Haemovigilance Network (IHN)**
R. de Vries (*The Netherlands*)

16.55 – 17.05

AUDITORIUM

CLOSING CEREMONY

Closing

G. Grazzini (*Italy*)